Read About the Latest News and Events at DRUGSCAN

ORAL FLUID TESTING 101: A TOXICOLOGIST’S VIEW - VIDEO
May 5, 2020 - Deborah Motika, MS, MS, D-ABFT-FT, TC (NRCC), MT(ASCP), senior vice president of toxicology shares her expertise about the benefits, accuracy, and versatility of oral fluid drug testing.
ORAL FLUID TESTING 101: A TOXICOLOGIST’S VIEW - Presentation Live Webinar on Real World Manipulation Techniques Used by Prescription Stimulant Drug Abusers Horsham, PA (May 6, 2019) - Researchers from DRUGSCAN® and Syneos Health® announced today that they will host a live, complimentary webinar titled, "Untangling methods to tamper with prescription stimulants: Perspectives from the bench-top to the real world” on Wednesday May 8, 2019 from 12:00 PM to 1:00 PM EDT. ACM Global Laboratories Announces Strategic Acquisition of DrugScan and DSI Medical Services Growing International Laboratory Business 2018/01/16 / ROCHESTER, N.Y. & HORSHAM, Pa - www.businesswire.com / Rochester Regional Health, a $2.2 billion integrated health care delivery system with more than 17,000 employees, has announced that wholly-owned subsidiary, ACM Global Laboratories, has added to its portfolio with the strategic acquisition of Philadelphia-based DrugScan, Inc. and DSI Medical Services, Inc. Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing - Journal of Opioid Management 2017 Nov/Dec;13(6):441-448 2017 Nov/Dec / PubMed / Authors Christopher Altomare, Eric Kinzler, August Buchhalter, Edward Cone and Anthony Costantino from DRUGSCAN and Pinney Associates review Category 1 testing requirements to satisfy FDA guidance for abuse-deterrent formulations. In Vitro "Chewing" Studies May Differentiate Abuse-Deterrent Formulations Suggests New Research from DRUGSCAN® and PinneyAssociates 2017/08/29 / PRNewsWire / Pharmaceutical companies developing abuse-deterrent formulations may be able to assess a formulation's ability to resist chewing, according to results of an in vitro "chewing" study conducted by DRUGSCAN© Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, and PinneyAssociates, leading experts in the evaluation of abuse-deterrent formulations. The results will be presented at PAINWeek 2017. Health care providers get update on drug testing: Experts call testing key to combating abuse 2017/08/16 / The Messenger -- Nearly 60 health care providers attended a seminar Tuesday at UnityPoint Health — Trinity Regional Medical Center aimed at improving the understanding of tools to use against the opioid epidemic prevalent across the nation. Untangling methods to tamper with opioid formulations: Perspectives from the benchtop to the real world This webinar features interviews with recreational and dependent prescription opioid abusers offering a rare look into the manipulation techniques abusers use to prepare opioid tablets for routes of administration that provide a more powerful euphoria, such as intravenous or intranasal. The webinar also discusses the laboratory experiments DRUGSCAN scientists conduct to evaluate the properties of abuse-deterrent formulations that are designed to resist these manipulation techniques Live Webinar on Real World Manipulation Techniques Used by Prescription Opioid Drug Abusers HORSHAM, Pa., June 19, 2017 /PRNewswire/ -- Researchers from DRUGSCAN® and INC Research® announced today that they will host a live, complimentary webinar titled, "Untangling methods to tamper with opioid formulations: Perspectives from the benchtop to the real world" on Wednesday June 28, 2017 from 12:00 PM to 1:00 PM EDT. Watch our latest webinar: In Vitro Mastication Studies for Abuse-Deterrent Formulations Eric Kinzler and Chris Altomare of DRUGSCAN discuss designing in vitro mastication studies for abuse-deterrent formulations. DRUGSCAN® to Present Scientific Data at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition HORSHAM, Pa., Nov. 14, 2016 /PRNewswire/ -- DRUGSCAN© Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, announced today that their scientists will be presenting data at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition held in Denver Colorado, from CAT.one® laboratory-based studies they conducted to assess the abuse-deterrent features of a polyethylene oxide (POLYOX™) based matrix formulation and the smoke-ability of opioid formulations. The data being presented can help guide developers of abuse-deterrent products. DRUGSCAN® to Present Scientific Data at the PAINWeek 2016 Conference HORSHAM, Pa., Aug. 30, 2016 /PRNewswire/ -- DRUGSCAN© Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, announced today that their scientists will be presenting data at the PAINWeek 2016 conference, from a study they conducted to assess the smoke-ability of opioids. Live Webinar on Best Practices and the FDA’s Abuse-Deterrent Guidance for Innovator and Generic Opioids Horsham, PA (April 27, 2016) – Experts from DrugScan®, PinneyAssociatessm, and INC Research® announced today that they will host a live, complimentary webinar titled, "Understanding the FDA's Abuse-Deterrent Guidance for Innovator and Generic Opioids - The Evolving Pathway for Development and Labeling", on Wednesday May 25, 2016 from 12:00 PM to 1:00 PM EDT. CAT.one™ Manipulation and Extraction Studies Satisfy FDA Requirements for Abuse-Deterrent Opioids Horsham, PA August 5, 2015 – DRUGSCAN© Pharmaceutical Services, a division of DRUGSCAN©, announced the introduction of CAT.one™ laboratory-based manipulation and extraction studies, designed to satisfy the US Food and Drug Administration’s (FDA) requirements for abuse-deterrent opioid pharmaceutical products. PinneyAssociates and DrugScan Collaborate to Offer In Vitro Tamper Testing of Abuse-Deterrent Drugs Bethesda, MD, April 21, 2014 -- PinneyAssociates and DrugScan announce a collaboration to provide in vitro laboratory tamper testing of abuse-deterrent drug products and formulations to pharmaceutical companies developing opioids and other drugs that act on the central nervous system. Phil Dubois to lead Drug Testing Industry Association The Drug and Alcohol Testing Industry Association (DATIA) held its annual meeting last week in Phoenix, Arizona and Phil Dubois took over as the new Chairman of the Board of Directors.